Transcode Therapeutics Inc (RNAZ)

$11.74 +0.74 (6.73%)
Market Cap 9.79M
Revenue (ttm) 0.00
Net Income (ttm) -16.75M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 66,100
Avg Vol 135,044
Day's Range N/A - N/A
Shares Out 834,000.00
Stochastic %K 36%
Beta 1.40
Analysts Strong Buy
Price Target $10.00

Company Profile

TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company's lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and t...

Industry: Biotechnology
Sector: Healthcare
Phone: 857-837-3099
Address:
6 Liberty Square, Suite 2382, Boston, United States
Abdujabbar90
Abdujabbar90 Jul. 25 at 7:50 PM
$RNAZ news coming
1 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 7:46 PM
( JFBR could open $20S tomorrow morning maybe been $40S to $50S ) Take notes from $ABVX $BMNR $SBET $VLCN $RNAZ
1 · Reply
Scoty_D
Scoty_D Jul. 24 at 6:47 PM
$RNAZ Fill that gap up, and let's get her going!
1 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 5:24 PM
JFBR I would watch this going into tomorrow and next week : ongoing catalysts and two separate merger deals : undervalue oversold 500K float .. 1st target $15-$20+ Second target could be high as $50+ We saw few low float recently $VLCN $58 from $5S $SBET 2s to $124 $RNAZ $CYCC $LIDR
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 5:00 PM
$CRE $8S now 100% going for $20+ next $JFBR tomorrow should get run $15-$20+ maybe even higher with news on the wire .. $VLCN gave the idea low $5S ran $58 recently $RNAZ $HSDT rent idea ran 130%+
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 4:01 PM
$NCNA 40%+ now since mentioned ✅ Watch $JFBR this week and next … update news pending ⏰✅ Could get a run like my $VLCN idea low $5S to $58 run recently ✅ $RNAZ idea yesterday 92% $HSDT swing idea ran 135% last week as well ✅
1 · Reply
Scoty_D
Scoty_D Jul. 24 at 2:43 PM
$RNAZ you ready?
0 · Reply
Mbacrunk06
Mbacrunk06 Jul. 24 at 12:36 PM
$RNAZ No premarket volume … like 10k … spike looks like a painted tape to bring in fomo at open
0 · Reply
OrangeDirt
OrangeDirt Jul. 24 at 11:35 AM
$RNAZ If anyone is still Short look for upgrades from Analysts soon They moved the stock to 17 yesterday for a reason I closed my Short at 10.92 this am
1 · Reply
Mbacrunk06
Mbacrunk06 Jul. 24 at 11:08 AM
$RNAZ Stock is stuck in premarket
0 · Reply
Latest News on RNAZ
TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

May 28, 2025, 8:00 AM EDT - 2 months ago

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

May 8, 2025, 8:05 AM EDT - 2 months ago

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

May 5, 2025, 5:07 PM EDT - 2 months ago

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

May 2, 2025, 4:10 PM EDT - 3 months ago

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

May 1, 2025, 9:01 AM EDT - 3 months ago

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

Apr 21, 2025, 4:37 PM EDT - 3 months ago

TransCode Therapeutics, Inc. Announces Adjournment of Special Meeting and Information for Adjourned Special Meeting

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

Mar 27, 2025, 4:37 PM EDT - 4 months ago

TransCode Therapeutics Announces Initial Dosing in Fourth Cohort of Phase 1 Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

Mar 25, 2025, 6:24 PM EDT - 4 months ago

TransCode Therapeutics, Inc. Announces Closing of Registered Direct Offering

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Mar 23, 2025, 11:11 PM EDT - 4 months ago

TransCode Therapeutics, Inc. Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

Mar 13, 2025, 7:47 AM EDT - 4 months ago

TransCode Therapeutics Announces Safety Review Committee Approval to Open Fourth Cohort in Phase I/II Clinical Trial

TransCode Therapeutics, Inc. Announces Results of Special Meeting

Feb 25, 2025, 4:15 PM EST - 5 months ago

TransCode Therapeutics, Inc. Announces Results of Special Meeting

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

Feb 6, 2025, 8:00 AM EST - 6 months ago

TransCode Therapeutics Announces Completion of Cohort 3 Initial Dosing with Lead Candidate in Phase 1 Clinical Trial

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Jan 14, 2025, 8:00 AM EST - 6 months ago

TransCode Therapeutics Announces First Patient Dosed in Third Cohort with Lead Candidate in Phase 1 Clinical Trial

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

Jan 7, 2025, 8:00 AM EST - 7 months ago

Nasdaq Determines That TransCode Therapeutics Has Regained Compliance with Continued Listing Requirements

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

Dec 18, 2024, 8:00 AM EST - 7 months ago

TransCode Therapeutics Announces Safety Review Committee Approval of Opening Third Cohort and Preliminary Results from First Cohort in Phase 1 TTX-MC138 Clinical Trial

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

Nov 29, 2024, 4:25 PM EST - 8 months ago

TransCode Therapeutics Announces Effective Date for 1-for-33 Reverse Stock Split

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

Nov 27, 2024, 7:00 AM EST - 8 months ago

TransCode Therapeutics, Inc. Announces $8 Million Private Placement

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

Nov 5, 2024, 7:00 AM EST - 9 months ago

TransCode Therapeutics Announces Nasdaq Extension to Regain Compliance

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

Sep 17, 2024, 7:00 AM EDT - 11 months ago

TransCode Therapeutics Announces First Patients Treated in Phase 1 Clinical Trial with First-in-Class Lead Therapeutic Candidate

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

Sep 5, 2024, 7:00 AM EDT - 11 months ago

TransCode Therapeutics Awarded $2 Million NIH Grant to Support Clinical Evaluation of Lead Candidate

TransCode Therapeutics, Inc. Announces Closing of Public Offering

Jul 24, 2024, 4:05 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Closing of Public Offering

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

Jul 22, 2024, 10:30 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Pricing of Public Offering

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

Jul 22, 2024, 4:07 PM EDT - 1 year ago

TransCode Therapeutics, Inc. Announces Proposed Public Offering of Common Stock

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

May 29, 2024, 9:15 AM EDT - 1 year ago

TransCode Therapeutics Reports Positive Data from First-in-Human Clinical Study Using Novel Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Open Letter to Shareholders

May 13, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Open Letter to Shareholders

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

Apr 15, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics Announces FDA Clearance To Initiate Phase 1/2 Clinical Trial with TTX-MC138 in Patients with Advanced Solid Tumors

TransCode Therapeutics Reports 2023 Results; Provides Business Update

Apr 3, 2024, 9:10 AM EDT - 1 year ago

TransCode Therapeutics Reports 2023 Results; Provides Business Update

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

Mar 28, 2024, 8:30 AM EDT - 1 year ago

TransCode Therapeutics Announces Appointment of Daniel Vlock, M.D., as Chief Medical Officer

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

Mar 11, 2024, 9:00 AM EDT - 1 year ago

TransCode Therapeutics and Akribion Genomics Report Progress Developing CRISPR-Derived Technology for Cancer Treatment

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

Mar 6, 2024, 4:15 PM EST - 1 year ago

TransCode Therapeutics To Present At 2024 RNA Leaders Europe Congress

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Feb 20, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Reports Publication of United States Patent Application Covering TransCode's RIG-I Agonist Immunotherapeutic

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

Jan 31, 2024, 4:05 PM EST - 1 year ago

Nasdaq Determines TransCode Therapeutics Compliance with Minimum Stockholders' Equity Requirement and Continued Listing on The Nasdaq Stock Market

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

Jan 29, 2024, 8:30 AM EST - 1 year ago

TransCode Therapeutics and Debiopharm Announce Collaboration to Develop Targeted Nucleic Acid Therapeutics for Cancer

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

Jan 22, 2024, 4:45 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $7.25 Million Public Offering

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

Jan 18, 2024, 1:27 PM EST - 1 year ago

TransCode Therapeutics Announces Pricing of $7.25 Million Public Offering

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

Jan 12, 2024, 4:05 PM EST - 1 year ago

TransCode Therapeutics Reports Further Restructuring to Reduce Expenses and Increased Focus on Planned Phase 1 Clinical Trial, Retirement of CEO

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

Jan 11, 2024, 8:00 AM EST - 1 year ago

TransCode Therapeutics Announces 1-for-40 Reverse Stock Split

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

Jan 4, 2024, 8:05 AM EST - 1 year ago

TransCode Therapeutics Publishes Open Letter Outlining Company's Progress and Objectives

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

Dec 12, 2023, 8:30 AM EST - 1 year ago

TransCode Therapeutics Reports Positive Pre-Clinical Results in Metastatic Pancreatic Cancer with its Lead Candidate, TTX-MC138

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

Dec 5, 2023, 9:00 AM EST - 1 year ago

TransCode Therapeutics To Present Phase 0 Data at 2023 San Antonio Breast Cancer Symposium

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Dec 4, 2023, 4:10 PM EST - 1 year ago

TransCode Therapeutics Announces Closing of $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

Nov 30, 2023, 2:53 PM EST - 1 year ago

TransCode Therapeutics Announces $1.2 Million Registered Direct Offering of Common Stock Priced At-The-Market under Nasdaq Rules

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

Nov 14, 2023, 4:30 PM EST - 1 year ago

TransCode Therapeutics Reports Third Quarter 2023 Results; Provides Business Update

TransCode Therapeutics Withdraws Public Offering

Oct 30, 2023, 4:33 PM EDT - 1 year ago

TransCode Therapeutics Withdraws Public Offering

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

Oct 27, 2023, 8:00 AM EDT - 1 year ago

Nasdaq Panel Grants TransCode Therapeutics Extension for Continued Listing on The Nasdaq Stock Market Subject to Conditions

TransCode Therapeutics Announces Public Offering of Common Stock

Oct 26, 2023, 4:19 PM EDT - 1 year ago

TransCode Therapeutics Announces Public Offering of Common Stock

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

Oct 26, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Announces Prolonged Survival in Murine Models with Glioblastoma Treated with Its Lead Candidate, TTX-MC138

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

Oct 24, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Announces Preliminary Clinical Results in First Patient in Phase 0 Clinical Study with Lead Therapeutic Candidate, TTX-MC138

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

Oct 16, 2023, 8:00 AM EDT - 1 year ago

TransCode Therapeutics Reports Successful Treatment of Preclinical Melanoma Tumors with its Immunotherapy Candidate, TTX-RIGA

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

Sep 28, 2023, 4:02 PM EDT - 1 year ago

TransCode Therapeutics Announces Closing of $8.5 Million Public Offering

Abdujabbar90
Abdujabbar90 Jul. 25 at 7:50 PM
$RNAZ news coming
1 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 7:46 PM
( JFBR could open $20S tomorrow morning maybe been $40S to $50S ) Take notes from $ABVX $BMNR $SBET $VLCN $RNAZ
1 · Reply
Scoty_D
Scoty_D Jul. 24 at 6:47 PM
$RNAZ Fill that gap up, and let's get her going!
1 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 5:24 PM
JFBR I would watch this going into tomorrow and next week : ongoing catalysts and two separate merger deals : undervalue oversold 500K float .. 1st target $15-$20+ Second target could be high as $50+ We saw few low float recently $VLCN $58 from $5S $SBET 2s to $124 $RNAZ $CYCC $LIDR
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 5:00 PM
$CRE $8S now 100% going for $20+ next $JFBR tomorrow should get run $15-$20+ maybe even higher with news on the wire .. $VLCN gave the idea low $5S ran $58 recently $RNAZ $HSDT rent idea ran 130%+
0 · Reply
ProfessorDman1
ProfessorDman1 Jul. 24 at 4:01 PM
$NCNA 40%+ now since mentioned ✅ Watch $JFBR this week and next … update news pending ⏰✅ Could get a run like my $VLCN idea low $5S to $58 run recently ✅ $RNAZ idea yesterday 92% $HSDT swing idea ran 135% last week as well ✅
1 · Reply
Scoty_D
Scoty_D Jul. 24 at 2:43 PM
$RNAZ you ready?
0 · Reply
Mbacrunk06
Mbacrunk06 Jul. 24 at 12:36 PM
$RNAZ No premarket volume … like 10k … spike looks like a painted tape to bring in fomo at open
0 · Reply
OrangeDirt
OrangeDirt Jul. 24 at 11:35 AM
$RNAZ If anyone is still Short look for upgrades from Analysts soon They moved the stock to 17 yesterday for a reason I closed my Short at 10.92 this am
1 · Reply
Mbacrunk06
Mbacrunk06 Jul. 24 at 11:08 AM
$RNAZ Stock is stuck in premarket
0 · Reply
TheDude2778
TheDude2778 Jul. 24 at 5:28 AM
$RNAZ —- Still holding going into PM. Say a prayer, but at least I’m not holding MULN
0 · Reply
Barker2258
Barker2258 Jul. 24 at 12:09 AM
$PBM Could be the next low float play. $RNAZ $PNPL -Banked on both of these today
1 · Reply
Adarali
Adarali Jul. 23 at 11:55 PM
$RNAZ tomorrow open premarket 1.60 $
0 · Reply
Scoty_D
Scoty_D Jul. 23 at 10:55 PM
$RNAZ Oh man, might be blessed with a round 2 with the VMAESA fella in the house!
1 · Reply
VMAESA
VMAESA Jul. 23 at 10:51 PM
$RNAZ Lmao hello bag holders
0 · Reply
diagio
diagio Jul. 23 at 8:24 PM
$RNAZ Nothing compared to the Italian Stallion @come_litaliano but these kind of gains times 2-4 tickers a day. Well you do the math. 🤣 Thanks again for the alert fellas @Discourse @ricky_lafleur
1 · Reply
SlapdaAskz
SlapdaAskz Jul. 23 at 8:03 PM
$RNAZ filled 🤑
1 · Reply
come_litaliano
come_litaliano Jul. 23 at 7:56 PM
$RNAZ That's how you make money @diagio
4 · Reply
diagio
diagio Jul. 23 at 7:53 PM
$RNAZ @ricky_lafleur @Discourse @come_litaliano Beautiful
0 · Reply
Whitewasabi
Whitewasabi Jul. 23 at 7:50 PM
$RNAZ Well this was turd haha
0 · Reply
Hovius
Hovius Jul. 23 at 7:49 PM
$RNAZ
0 · Reply
topstockalerts
topstockalerts Jul. 23 at 7:44 PM
$RNAZ what will she do AH?🚨..🚨
0 · Reply